45 results
424B5
NKTX
Nkarta, Inc.
25 Mar 24
Prospectus supplement for primary offering
8:15pm
in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”);
reduced
8-K
EX-99.1
esdm9
25 Mar 24
Regulation FD Disclosure
6:05am
8-K
EX-99.1
abvdxuuuyv3g6rl6zqf
8 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-99.1
9folq7e5aghl4f 2q
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
8-K
EX-99.2
skbtwev9okvlbq3 n9
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
PRE 14A
iqlgq
14 Apr 23
Preliminary proxy
5:00pm
8-K
EX-99.2
dqhgki
5 Dec 22
Regulation FD Disclosure
7:39am
8-K
EX-99.1
xwcjgvmk
5 Dec 22
Regulation FD Disclosure
7:39am